Eric Verdin at ARDD2025: Targeting CD38 against aging
Keywords
Summary
146 words
Critical Evaluation
Value of the Information & Strength of the Argument
The presentation provides valuable insights into a novel approach to combating aging by targeting CD38. The argumentation is solid, supported by experimental data from knockout mice and a novel inhibitor. The speaker effectively critiques the current paradigm of NAD supplementation, offering a logical alternative. The data presented are preliminary but compelling, with clear evidence of cognitive improvement and molecular changes consistent with rejuvenation. The argumentation is well-structured, moving from basic observations to mechanistic insights and potential therapeutic applications.
Scientific Rigor, Source Quality, Title Accuracy
The scientific rigor is high, with data from well-controlled experiments, including knockout mice and a novel inhibitor. The speaker references key studies, such as those by Eduardo Chini, and acknowledges ongoing work. The title accurately reflects the content, focusing on CD38 as a target against aging. The presentation is from a reputable institution (Buck Institute) and a major conference (ARDD), adding credibility. However, some claims lack detailed statistical analysis, and the story is acknowledged as incomplete.
169 words
Title / Content Match
The title accurately reflects the content, focusing on CD38 as a target against aging.
Quality & Reliability
8/10
Presentation of original research data from a leading aging research institute, with clear methodology and preliminary results. Some claims lack detailed statistical context, but the overall approach is rigorous.
Key Moments
Markers derived by PSI from the transcript: the creator did not define chapters.
- Introduction to NAD metabolism and its role in aging.
- Discussion of NAD decline with age and the 'leaky sink' model.
- Introduction of CD38 as a key NAD-consuming enzyme.
- Evidence of CD38 increase in brain aging and its localization in choroid plexus.
- Cognitive benefits in CD38 knockout mice.
- Identification of CD38 in pericytes of choroid plexus.
- Multi-omics analysis showing reversal of aging phenotype in choroid plexus.
- Metabolomics and transcriptomics of hippocampus.
- Development of novel CD38 inhibitor NTX-748 and its effects.
- Summary and acknowledgments.
Cited Sources
- Eduardo Chini's papers on CD38 and NAD — Referenced as key studies showing CD38 knockout restores NAD levels in mice.
Concurring Sources
- Eduardo Chini's papers on CD38 and NAD — Referenced as key studies showing CD38 knockout restores NAD levels in mice.
Contribution & Novelties
This presentation offers novel insights into the role of CD38 in brain aging, particularly its unexpected localization in choroid plexus pericytes. The finding that CD38 knockout reverses aging-related gene expression in the choroid plexus and hippocampus is a significant contribution. The development of a new CD38 inhibitor (NTX-748) with promising preclinical results adds translational value.
Pour aller plus loin :
- NAD+ metabolism and aging — Overview of NAD+ and its role in aging.
- CD38 — General information on CD38 protein.
- Choroid plexus — Structure and function of the choroid plexus.
90 words
Radar Profile
The radar profile shows high scores across all dimensions, indicating a well-rounded presentation with strong scientific content, technical depth, and reliability. The balance between information quantity and quality is particularly notable.